FAU.de
Deutsch
Login
Home
Publications
Research Grants
Inventions & Patents
Awards
Additional Research Activities
Faculties & Institutions
Research Areas
Prof. Dr. med. Peter Fasching
List of publications:
BibTeX-Download
Professur für Translationale Frauenheilkunde und Geburtshilfe
Project Leads
(2)
Project Memberships
(2)
Publications
(796)
Types of publications
Toggle all
Journal article
Journal article
Book chapter / Article in edited volumes
Book chapter / Article in edited volumes
Authored book
Authored book
Translation
Translation
Thesis
Thesis
Edited Volume
Edited Volume
Conference contribution
Conference contribution
Other publication type
Other publication type
Unpublished / Preprint
Unpublished / Preprint
Publication year
From
To
Abstract
Journal
Filters (inactive)
Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial (2021)
Fehm T, Mueller V, Banys-Paluchowski M, Fasching P, Friedl TWP, Hartkopf A, Huober J, et al.
Conference contribution
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program (2021)
Muller V, Banys-Paluchowski M, Friedl TWP, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, et al.
Journal article
Global Phase 3 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy (2021)
Rugo H, Chow LWC, Cortes J, Fasching P, He XB, Hsu P, Huang CS, et al.
Conference contribution
Phase II neoadjuvant study of GDC-9545+palbociclib (palbo) vs anastrozole (A) plus palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC) (2021)
Hurvitz SA, Fasching P, Park YH, Quiroga V, Crnjevic TB, Fresco R, Lopez-Valverde V, et al.
Conference contribution
ABEMACARE: Abemaciclib in combination with endocrine therapy as first line therapy in metastatic breast cancer patients with symptomatic visceral metastases or high tumor burden (2021)
Kotzur F, Bidner H, Bronger H, Egert S, Fasching P, Fischer D, Kehl V, et al.
Conference contribution
Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry—comparison of three different GPA prognostic scores (2021)
Riecke K, Müller V, Weide R, Schmidt M, Park‐simon TW, Möbus V, Mundhenke C, et al.
Journal article
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial (2021)
Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, et al.
Journal article
Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2-Advanced Breast Cancer (2021)
Fasching P, Delea TE, Lu YS, De Boer R, Hurvitz SA, Moynahan A, Chandiwana D, et al.
Journal article
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer (2021)
Schneeweiss A, Michel LL, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, et al.
Journal article
Erratum: AGO Recommendations for the Surgical Therapy of the Axilla after Neoadjuvant Chemotherapy: 2021 Update (Geburtshilfe Frauenheilkd (2021) 81:10 (1112-1120) DOI: 10.1055/a-1499-8431) (2021)
Friedrich M, Kühn T, Janni W, Müller V, Banys-Paluchowski M, Kolberg-Liedtke C, Jackisch C, et al.
Journal article, Erratum
‹
1
...
23
24
25
26
27
...
80
›